However, 80%-90% of CRC patients who got mutations in EGFR or downstream signal pathway molecules, including KRAS, BRAF, PI3K catalytic subunit alpha (PI3KCA), and PTEN, did not respond well to cetuximab [37]. This evidence concerns the gene EGFR and colorectal carcinoma.